Molecular docking coupled with molecular dynamics simulations was employed to evaluate the binding patterns and dynamic stability of Resmetirom—a drug approved for the treatment of nonalcoholic fatty liver disease in adults—with the protein structures of ERN1 and SLC11A1. Here, ERN1 is linked to metabolic dysfunction-associated steatotic liver disease.